Type of Article: Review

Page No.: 110-113

DOI: 10.16965/ijims.2015.114

 

Current Prescribing Pattern of Antihypertensive Drugs in Preeclampsia

Sujit Kumar Sarker *1, Kumar Ganesan 1, Ratna Paul 2.

*1 Faculty of Medicine, International Medical School, Management & Science University, Shah Alam, Selangor, Malaysia.

2 Mohammadpur Fertility Services & Training Centre, Mohammadpur, Dhaka, Bangladesh.

 

ABSTRACT

Introduction: Preeclampsia is a medical disorder encountered during pregnancy. It is a multisystem disorder characterized by new onset of hypertension presenting after 20 weeks of gestation with clinically relevant proteinuria. Failure to control blood pressure can affect both mother and fetus health.

Methods: The present study was evaluated and collected the data from Pubmed and Google Scholar databases since 2010 to 2014 and summarized current pattern of antihypertensive drugs used in preeclampsia.

Results: Among the antihypertensive drugs most commonly preferred drugs in mild to moderate hypertension by clinicians are alpha methyldopa, labetalol and nifedipine.

Conclusion: The pattern of antihypertensive drugs for treatment of preeclampsia remain same for many years due to limited clinical trials of alternative drugs.

KEY WORDS: Preeclampsia, Antihypertensive, Pregnancy, Prescribing pattern.

 

REFERENCES

  1. Easterling TR. Pharmacological management of hypertension in pregnancy. Semin Perinatol 2014;38(8):487-95.
  2. Kattah AG, Garovic VD. The management of hypertension in pregnancy. Adv Chronic Kidney Dis 2013;20(3):229-39.
  3. Szczepaniak-Chicheł L, Tykarski A. Treatment of arterial hypertension in pregnancy in relation to current guidelines of the Polish Society of Arterial Hypertension from 2011. Ginekol Pol. 2012;83(10):778-83.
  4. Duley L. Pre-eclampsia, eclampsia, and hypertension. BMJ Clin Evid. 2011, pii: 1402.
  5. Lambert G, Brichant JF, Hartstein G, Bonhomme V, Dewandre PY. Preeclampsia: an update. Acta Anaesthesiol Belg 2014;65(4):137-49.
  6. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S: Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010, 341: c2207.
  7. Brown CM, Garovic VD. Mechanisms and management of hypertension in pregnant women. Curr Hypertens Rep. 2011;13(5):338-46.
  8. Magee LA, Abalos E, von Dadelszen P, Sibai B, Easterling T, Walkinshaw S. How to manage hypertension in pregnancy effectively. Br J Clin Pharmacol. 2011;72(3):394-401.
  9. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014;2:CD002252.
  10. Kumar S, Bansal D, Hota D, Jain M, Singh P, Pandey BL. Assessment of clinical outcomes and prescribing behavior among inpatients with severe preeclampsia and eclampsia: an Indian experience. Indian J Pharmacol. 2014;46(1):18-23.
  11. Lalani S, Firoz T, Magee LA, Sawchuck D, Payne B, Gordon R, Vidler M, von Dadelszen P. Pharmacotherapy for preeclampsia in low and middle income countries: an analysis of essential medicines lists. J Obstet Gynaecol Can. 2013;35(3):215-23.
  12. Firoz T, Magee LA, MacDonell K, Payne BA, Gordon R, Vidler M, von Dadelszen P. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG.2014;121(10):1210-8.
  13. Vest AR, Cho LS. Hypertension in pregnancy. Cardiol Clin. 2012;30(3):407-23.
  14. Carles G, Helou J, Dallah F, Ibrahim N, Alassas N, Youssef M. Use of injectable urapidil in pregnancy-induced hypertension and preeclampsia. J Gynecol Obstet Biol Reprod (Paris). 2012;41(7):645-9.
  15. Buch J. Urapidil, a dual-acting antihypertensive agent: Current usage considerations. Adv Ther. 2010;27(7):426-43.
  16. Jennifer Uzan, Marie Carbonnel, Olivier Piconne, Roland Asmar and Jean-Marc Ayoubi. Pre-eclampsia: pathophysiology, diagnosis, and management. Vasc Health Risk Manag. 2011;7:467–474.
  17. Xu B, Charlton F, Makris A, Hennessy A. Antihypertensive drugs methyldopa, labetalol, hydralazine, and clonidine improve trophoblast interaction with endothelial cellular networks in vitro. J Hypertens. 2014;32(5):1075-83.
  18. Amaral LM, Pinheiro LC, Guimaraes DA, Palei AC, Sertório JT, Portella RL, Tanus-Santos JE. Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia. J Cell Mol Med. 2013;17(10):1300-7.
  19. Mizutani S, Wright J, Kobayashi H. A new approach regarding the treatment of preeclampsia and preterm labor. Life Sci. 2011;88(1-2):17-23.
  20. Arulkumaran N, Lightstone L. Severe pre-eclampsia and hypertensive crises. Best Pract Res Clin Obstet Gynaecol. 2013;27(6):877-84.
  21. Xie RH, Guo Y, Krewski D, Mattison D, Nerenberg K, Walker MC, Wen SW. Trends in using beta-blockers and methyldopa for hypertensive disorders during pregnancy in a Canadian population. Eur J Obstet Gynecol Reprod Biol. 2013;171(2):281-5.
  22. Liu QQ, Yu YH, Gong SP, Huang LP. Clinical efficacy and perinatal outcome of nifedipine for severe preeclampsia: meta-analysis. Zhonghua Fu Chan Ke Za Zhi. 2012;47(8):592-7.
  23. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31(1):70-85.
  24. Solomon CG, Seely EW. Hypertension in pregnancy. Endocrinol Metab Clin North Am. 2011;40(4):847-63.
  25. Fabry IG, Richart T, Chengz X, Van Bortel LM, Staessen JA. Diagnosis and treatment of hypertensive disorders during pregnancy. Acta Clin Belg. 2010;65(4):229-36.
  26. C W G Redman: Hypertension in pregnancy. the NICE guidelines. Heart 2011;97:1967-1969.
  27. Tessa E. R. Gillon, Anouk Pels, Peter von Dadelszen, Karen MacDonell, and Laura A. Magee. Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines. PLoS One. 2014;9(12):e113715.
  28. Tallarek AC, Stepan H. Preeclampsia and HELLP syndrome as an obstetric emergency. Med Klin Intensivmed Notfmed. 2012;107(2):96-100.

 

Download Full Text TOC